BioSpace

Neurogene, Taysha near finish line in ‘two-horse race’ for first Rett syndrome gene therapy

As both Taysha Gene Therapies and Neurogene warm up for an important year of readouts, the Rett syndrome community is pinning hopes on a smooth finish—and possibly, a result in line with Novartis’ spinal muscular atrophy gene therapy Zolgensma.

By BioSpace

1 min read
Neurogene, Taysha near finish line in ‘two-horse race’ for first Rett syndrome gene therapy
AI-generated illustration

Got news to share with the events industry?

Submit a press release or story tip and reach thousands of event professionals.

Get in touch→

More in Health Tech

Related Insights